Zenner and colleagues. Despite effective treatments, researchers warn that global progress is falling far short of World Health Organization End TB Strategy targets, driven by persistent diagnostic gaps, funding shortages, and drug-resistant strains.
Global Tuberculosis Burden and Incidence Trends
An estimated 10.7 million people developed tuberculosis in 2024, a figure that includes roughly 620,000 individuals living with HIV, according to the review. While overall global incidence fell by 1% between 2023 and 2024, infection rates remain higher than pre-COVID-19 pandemic levels. Men account for more than half of all reported cases, while children continue to represent a substantial proportion of infections due to ongoing community transmission and missed opportunities for early diagnosis.
The geographic distribution of the disease remains heavily concentrated. According to the review, 30 high-burden countries account for 87% of all tuberculosis cases globally. India, Indonesia, the Philippines, China, Pakistan, Nigeria, the Democratic Republic of the Congo, and Bangladesh contribute the largest shares of the global caseload.
Did You Know?
Researchers estimate that approximately one-quarter of the world’s population has been infected with Mycobacterium tuberculosis. While most never develop active disease, individuals with clinical and social vulnerabilities face a significantly higher risk of progression.
Diagnostic Gaps and Case Detection Challenges
Global case detection saw improvements in 2024, with 8.3 million cases officially notified—representing 78% of the estimated total disease burden, according to the authors. This improvement was largely driven by the expanded deployment of rapid molecular diagnostics. However, prevalence surveys consistently identify large numbers of bacteriologically confirmed yet asymptomatic cases, indicating that many infectious individuals remain undiagnosed within communities.
Vulnerabilities such as undernutrition, HIV infection, diabetes, smoking, harmful alcohol use, air pollution, migration, and conflict continue to fuel the epidemic, particularly across low- and middle-income nations. These social determinants mean that medical intervention alone cannot break transmission chains without parallel economic and public health support.
The Threat of Drug-Resistant Tuberculosis
Drug-resistant strains continue to present a severe obstacle to global eradication efforts. Out of an estimated 390,000 multidrug-resistant or rifampicin-resistant tuberculosis cases in 2024, only 42% of patients actually began treatment, according to the review data. Although treatment success rates improved to reach 71% for those treated, the large volume of undiagnosed and untreated individuals remains a critical public health vulnerability.
Preventive therapies are also severely underutilized. In 2024, tuberculosis-preventive treatment reached 5.3 million people. This total included 58% of eligible people living with HIV, but only 25% of eligible household contacts—metrics that fall well below international public health targets.
Public Health Priority
According to the authors of the review, closing the treatment gap requires expanding proactive case finding and scaling up access to preventive therapy for vulnerable household contacts and high-risk groups.
Funding Shortfalls and Investment Needs
Eliminating the disease will demand a dramatic shift in political commitment and financial backing. Current funding stands at only 27% of global targets, creating massive deficits across prevention, diagnostic rollout, treatment programs, and public health infrastructure. Without increased investment to sustain diagnostics and strengthen social protection programs, researchers caution that the World Health Organization goals will remain out of reach.
Frequently Asked Questions
What is the leading cause of death from a single infectious pathogen?
Tuberculosis remains the leading infectious killer globally, claiming an estimated 1.23 million lives in 2024, according to The Lancet Microbe review.
How many people developed tuberculosis in 2024?
Researchers estimate that 10.7 million people developed tuberculosis worldwide in 2024, including approximately 620,000 people living with HIV.
What are the primary barriers to eliminating tuberculosis?
Major barriers include persistent diagnostic gaps, inadequate funding, drug-resistant strains, and broader social inequalities such as undernutrition, poverty, and diabetes.
How effective is treatment for drug-resistant tuberculosis?
While treatment success rates reached 71% for those who started therapy, only 42% of an estimated 390,000 multidrug-resistant or rifampicin-resistant cases actually began treatment in 2024.
Stay Informed on Global Health Trends
Explore our latest reporting on international public health initiatives, medical research breakthroughs, and global disease prevention strategies. Subscribe to our newsletter to receive updates directly to your inbox.
Related reading